Ivonescimab Plus Chemotherapy Fails Cost-Effectiveness Test in Advanced Squamous Lung Cancer
A cost-effectiveness model based on the HARMONi-6 trial finds that ivonescimab plus chemotherapy is unlikely to be cost-effective for advanced ...
A cost-effectiveness model based on the HARMONi-6 trial finds that ivonescimab plus chemotherapy is unlikely to be cost-effective for advanced ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine